The optimal strategy for cardiovascular (CV) disease surveillance in kidney transplant candidates is uncertain. In this observational study of 604 wait-listed patients in British Columbia, the risk for CV event in diabetic and nondiabetic candidates was 12.7 and 4.5% per year, respectively. CV event rates were relatively constant during the first 3 yr of wait-listing (5.3 to 6.6 per 100 patient-years; 95% confidence interval [CI], 3.7 to 9.3) but rose dramatically during the peritransplantation period (39.6/100 patient-years; 95% CI, 20.6 to 76.1) and remained high throughout the first posttransplantation year (4.0 per 100 patient-years; 95% CI, 2.2 to 7.5). The results of noninvasive cardiac investigations before wait-listing were not predictive of the time to CV event after wait-listing. The practice of surveillance cardiac investigation in wait-listed patients on the basis of ongoing clinical assessment of cardiac risk resulted in fewer investigations (n ‫؍‬ 171) than with the recommended practice of periodic screening on the basis of waiting time alone (n ‫؍‬ 530) and was not associated with an increased frequency of CV events (CV event rate in patients with and without the recommended frequency of investigation was 9.9 [95% CI, 7.1 to 13.7] and 6.7 [95% CI, 5.2 to 8.7] per 100 patient-years). It is concluded that transplant candidates are at high risk for CV events particularly during the perioperative period. Initial cardiac investigations have limited value in guiding the timing of patient reevaluation after wait-listing. Periodic surveillance cardiac investigation after wait-listing may be unnecessary and requires further study.
T he discrepancy between the supply of organs that are available for transplantation and the demand for cadaveric kidney transplantation continues to increase. As of June 2004, there were 58,590 patients on the United Network of Organ Sharing waiting list for kidney transplantation (http://www.unos.org). Under present conditions, an estimated 95,000 patients will be waiting for a kidney transplant by 2010, and waiting times of a decade or more are anticipated (1) . In addition, the medical complexity of the wait-listed population is likely to increase as the age and the comorbidity of transplant candidates increases and as more patients with allograft failure return to the waiting list (2) . Because of these factors, more health care resources will be required to monitor and maintain the medical fitness of transplant candidates in the future. The consequences of failure to maintain the medical fitness of transplant candidates include death on the waiting list, candidate refusal at the time of transplantation resulting in psychologic strain for the refused candidate and prolonged cold ischemic time for the eventual recipient, and increased morbidity and mortality after transplantation.
Comprehensive medical evaluation at the time of activation to the transplant waiting list as well as frequent reevaluation of the medical fitness of transplant candidates may be necessary because of the high incidence and prevalence of cardiovascular (CV) disease in chronic kidney disease patients (3, 4) . Although published clinical guidelines for the initial cardiac evaluation of patients who seek kidney transplantation as well as recommendations for the medical surveillance of patients who are on the waiting list are available, these recommendations are primarily based on consensus opinion (5, 6) . A recent American Society of Transplantation survey found wide variation in the medical surveillance of wait-listed patients, including the frequent use of expensive cardiac investigations (7) . As waiting times continue to increase, development of evidence-based strategies to optimize the medical management and surveillance of waitlisted patients is clearly needed.
Currently, there is a paucity of information regarding the CV event rates on the transplant waiting list or the optimal use of investigations for cardiac disease in transplant candidates. We performed a prospective observational study to determine the incidence and the timing of CV events and the frequency of cardiac investigations among adult kidney transplant candidates in the province of British Columbia, Canada, between 1998 and 2002. We determined whether the results of initial cardiac investigations before activation to the waiting list could be used to guide the timing of patient reevaluation after waitlisting and determined the CV event rates among wait-listed patients who underwent surveillance cardiac investigations more frequently or less frequently than recommended in recently published consensus guidelines (5, 6) .
Materials and Methods

Patient Population and Study Design
Beginning in July 1998, we began a prospective study of adult (age Ն18 yr) patients who were on the kidney transplant waiting list in British Columbia. The population of British Columbia is 3.9 million, and the incidence of treated end-stage kidney disease (dialysis or transplantation) is approximately 140 per million with approximately 550 incident patients per year (8) . During the study period, 30 to 35% of the chronic adult dialysis patients were also on the transplant waiting list (8) . The study included 349 prevalent wait-listed patients and 255 incident patients who were activated to the transplant waiting list between July 1998 and October 2001.
Detailed clinical and demographic data were collected from the initial transplant assessment. All adult transplant candidates received a structured medical assessment by a consistent group of transplant physicians in one of two provincial transplant centers before activation to the transplant waiting list. This assessment included a medical history, physical examination, and electrocardiogram (ECG). Before 2001, there were no established guidelines regarding the use of noninvasive cardiac investigations in the initial evaluation of kidney transplant candidates (9, 10) . Therefore, cardiac investigations before activation to the waiting list were performed at the discretion of the transplant physician.
After wait-listing, investigations for CV disease were performed when clinically indicated or at the discretion of the transplant physician. All study patients underwent biannual structured interviews by a dedicated research assistant to determine the incidence of any new CV events as well as the completion of any new cardiac investigations. All CV events and investigations during follow-up were confirmed, and the cause of death was determined by review of medical records in all cases. Patients were followed until death, removal from the waiting list for noncardiac reasons, 1 year after transplantation, or the end of the study period (October 2002). The study was approved by the local hospital ethics committee for human experimentation, and all study patients provided informed consent.
Analytical Methods
Classification of Cardiac Risk
In the absence of a validated index to predict cardiac risk in patients who undergo kidney transplant surgery (9), we classified patients as high, intermediate, or low cardiac risk on the basis of the following three risk factors: age (Ն45 yr for men and Ն55 yr for women), history of diabetes, and history of ischemic heart disease. Patients with two or more risk factors were high risk, patients with one risk factor were intermediate risk, and patients without risk factors were low risk.
Definition of Comorbid Conditions
Comorbid conditions at the initial transplant assessment were defined as follows: Ischemic heart disease (IHD) was defined by history of myocardial infarct, coronary artery bypass grafting (CABG), or percutaneous coronary angioplasty (PTCA); the presence of a Q wave infarct on ECG, or any presence of ischemia on thallium/sestamibi with exercise or dipyridamole (MIBI). Abnormal left ventricular systolic function was defined as class 2 or greater congestive heart failure according to the New York Heart Association Classification or an ejection fraction of Յ40% on echocardiogram or radioisotope determination (multiple gated acquisition). Peripheral vascular disease was defined as symptoms of claudication, limb amputation, or history of extremity revascularization.
Cardiac Testing
Initial cardiac tests included all cardiac investigations and interventions performed in a 6-mo period before activation to the transplant waiting list. Patients within the low, intermediate, and high cardiac risk groups were characterized by the type and the result of the initial cardiac investigations as having (1) ECG only; (2) noninvasive investigations only (MIBI or two-dimensional echocardiography), which were considered abnormal when the ejection fraction was Յ40% (echocardiogram) or when any degree of ischemia was noted on myocardial perfusion study; or (3) invasive investigations and interventions (coronary angiography, percutaneous coronary angioplasty [PTCA], or CABG).
After activation to the waiting list, cardiac investigations may have been performed because of symptoms or for medical surveillance of asymptomatic transplant candidates. To exclude investigations performed during an evolving or completed CV event, we defined surveillance noninvasive cardiac investigations (MIBI or two-dimensional echocardiography) as those that were performed at least 90 d from the date of a CV event.
Outcome
The composite end point of any CV event after activation to the waiting list was the primary outcome measure and included cardiac death, myocardial infarction, PTCA, CABG, completed stroke, and removal from the transplant waiting list for cardiac reasons.
Statistical Analyses
The characteristics of the study patients were described as the mean and SD for continuous variables and frequency for categorical variables, unless otherwise indicated, and group differences were tested with the 2 test or t test as appropriate. The demographic characteristics of the study patients were compared with those of the prevalent nonwait-listed dialysis population aged 18 to 70 yr in British Columbia in December 1999. Among study patients, demographic and clinical characteristics, including the use of cardioprotective medications (angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, ␤-blockers, and lipid lowering medications), were compared between patients in the low, intermediate, and high cardiac risk groups. CV disease event rates (composite end point) as well rates of myocardial infarction and cardiac death were determined during the period of wait-listing and during the first posttransplantation year. These calculations were performed using Poisson regression. The Poisson rates were used to calculate the probability of CV event (per year). Within the high, intermediate, and low cardiac risk groups, the time to first CV event after activation to the waiting list was determined using the Kaplan-Meier method, and group differences were tested with the log-rank test. To determine whether the results of noninvasive cardiac investigations performed during the initial transplant assessment could guide the timing of medical revaluation among patients in the different cardiac risk groups, we also determined the time to first CV event among patients with either normal or abnormal initial noninvasive cardiac investigations.
The rate of surveillance noninvasive cardiac investigation (MIBI or two-dimensional echocardiography) in subgroups of wait-listed patients was compared with the recommended rate of investigation (5) . In patients with normal tests before wait-listing, surveillance cardiac investigation is recommended annually in diabetic patients, biannually in patients with a history of IHD or peripheral vascular disease, and every 3 yr in patients at low risk (i.e., no diabetes, IHD, or peripheral vascular disease). In patients with abnormal tests before wait-listing, surveillance cardiac investigation is recommended annually in those with no revascularization or PTCA and every 3 yr in those with successful CABG. We then determined the CV event rates among patients with and without the recommended frequency of investigation. For this analysis, we excluded CV events that may have been the direct result of surveillance cardiac investigation (e.g., revascularization procedures in asymptomatic patients with ischemia demonstrated on noninvasive surveillance testing) and considered only CV events that occurred at least 90 d after the completion of a surveillance investigation. All statistical analyses were performed with SAS software version 8.2 (SAS Institute, Cary, NC).
Results
Patient Characteristics
Of the 632 patients who were either on the waiting list at study inception or activated to the waiting list after the study start, 604 provided written consent and participated in the study. Table 1 shows the demographic characteristics of study patients and of the non-wait-listed prevalent dialysis population aged 18 to 70 yr in British Columbia in December 1999. The distribution of race in the dialysis and wait-listed patients was representative of the general population in British Columbia. The majority of patients were of white race, there was a large proportion of Asian patients, and there were only five black patients (grouped as other). The study patients were younger and less likely to have diabetes compared with non-wait-listed patients. Table 2 compares the demographic characteristics, cardiac investigations performed before activation to the waiting list, and use of cardioprotective medications among study patients in the different cardiac risk groups. Forty percent of all study patients were activated to the waiting list before starting dialysis. High cardiac risk patients had more noninvasive and invasive cardiac investigations performed before wait-listing. The use of cardioprotective medications was uncommon, and only 20 to 45% of high-risk patients received angiotensin-converting enzyme inhibitors, ␤-blockers, or lipid-lowering medications either at the time of wait-listing or at the end of study follow-up.
CV Events
During the mean follow-up period of 3.7 Ϯ 1.8 yr, 69 patients had CV events on the waiting list, including 28 deaths ( Figure  1) . Among the 30 patients who remained on the waiting list after an initial CV event, 12 sustained additional CV events, including nine deaths. Among patients without CV events on the waiting list, 267 received transplants after a mean waiting time of 2.6 Ϯ 1.6 yr. Among transplant recipients, there were 16 CV events in the first posttransplantation year, including six deaths. Seven of these 16 CV events occurred in the first 30 d after transplantation, including two deaths.
The CV event rate among all patients on the waiting list was 6.1/100 patient-years (95% confidence interval [CI], 5.1 to 7.2), and the death rate was 1.6/100 patient-years (95% CI, 1.2 to 2.2). The CV event rate among Asian patients was 4.3/100 patient-years (95% CI, 2.7 to 6.9) compared with 6.7/100 patient-years (95% CI, 5.4 to 8.3) in patients of white race. The CV event rate among patients who were activated to the waiting list before dialysis (5.2/100 patient-years; 95% CI, 3.9 to 6.9) was lower than in patients who were wait-listed after starting dialysis (6.9/100 patient-years; 95% CI, 5.4 to 8.1). The probability of any CV event per year on the waiting list for patients with diabetes was 12.7% (95% CI, 9.7 to 16.4) and was 4.5% (95% CI, 3.7 to 5.6) for nondiabetic patients. The probability of death per year on the waiting list for patients with and without diabetes was 3.4% (95% CI, 2.0 to 5.9) and 1.2% (95% CI, 0.8 to 1.9), respectively. In the first posttransplantation year, the probability of a CV event among patients with diabetes was 18.9% (95% CI, 10.1 to 33.6) and 5.8% (95% CI, 3.3 to 10.1) for nondiabetic patients. The probability of death in the first posttransplantation year among patients with and without diabetes was 9.7% (95% CI, 3.8 to 23.7) and 2.4% (95% CI, 1.0 to 5.7), respectively. Figure 2 shows the CV event rates per 100 patient-years among study patients in the three cardiac risk groups during the first 3 yr on the waiting list and during the first posttransplantation year. Cardiac event rates on the waiting list remained relatively constant over time. Event rates were highest in the peritransplantation period (first 2 wk posttransplantation) and then rapidly decreased but remained at or above the rates during the waiting list period throughout the entire first posttransplantation year. The increase in event rates during the first posttransplantation year was largest among patients in the high cardiac risk group. Figure 3 shows that after activation to the waiting list, CV events were more frequent among patients in the higher cardiac risk groups. Figure 4 shows the time to first CV event among the patients who were in low, intermediate, and high cardiac risk groups and had only noninvasive cardiac investigations before waitlisting. The results of noninvasive cardiac investigations before activation to the waiting list were not predictive of the time to CV event among patients in the low, intermediate, and high cardiac risk groups. Table 3 compares our use of surveillance noninvasive investigations (MIBI or two-dimensional echocardiography) in waitlisted patients with that recommended by recently published guidelines (5) . Our use of surveillance cardiac investigation (total of 171 investigations performed) was much lower than the number of investigations that would be required according to current recommendations (n ϭ 530). The CV event rates among patients with fewer than the recommended number of surveillance investigations were either lower than or no different from those among patients who were at similar cardiac risk and were investigated at or above the recommended frequency. 
Initial Cardiac Investigations and CV Events
Discussion
In this observational study of adult patients on the kidney transplant waiting list, we found that CV events were common and that the frequency of CV events dramatically increased during the peritransplantation period and remained high throughout the first posttransplantation year. We classified patients into high, intermediate, and low cardiac risk groups on the basis of age, gender, and history of comorbid conditions (diabetes and IHD) and found that this simple classification was predictive of the time to first CV event on the waiting list. The results of initial noninvasive cardiac investigations before wait-listing were of limited value in guiding the timing of patient reevaluation after wait-listing. Our use of surveillance noninvasive cardiac investigation on the basis of clinician assessment of risk was much lower than the suggested frequency of investigation on the basis of waiting time, and we found no evidence that our more selective practice was associated with an increase in CV events. Given the workload and cost of patient assessment and cardiac investigation, randomized, prospective studies to define optimum strategies for the assessment of patients who are on the transplant waiting list are needed.
Although rates of death and patient removal from the transplant waiting list are available from the United Network of Organ Sharing web site (http://www.unos.org), detailed information regarding CV events on the waiting list is needed to develop CV disease surveillance programs. The death rate on the waiting list in our population (1.6/100 patient-years) was lower than the death rate among wait-listed patients in the United States during the same time period (6.6 to 6.9/100 patient-years; http://www.unos.org). Demographic differences between our population and the wait-list population in the United States may underlie some of the difference in death rates. The age, diabetic status, and comorbid disease characteristics of our population were representative of the wait-listed population in the United States (http://www.unos.org). Asian patients and patients who were activated to the waiting list before starting dialysis comprised a larger proportion of our study population compared with the wait-listed population in the United States (http://www.unos.org) (11) , and these patients had relatively lower CV event rates. Asian patients are known to have the lowest mortality of any racial group on the UNOS waiting list (http://www.unos.org). The lower CV event rates among patients who are wait-listed before dialysis may be related to decreased dialysis exposure.
The time course of CV events after wait-listing in our study ( Figure 2 ) was similar to the risk for mortality described for transplant candidates who undergo cadaveric kidney transplantation (12) . However, of concern, we found a sustained high rate of CV events throughout the first posttransplantation year that has not been previously described. The pattern of CV events in our study suggests several opportunities for intervention. Aggressive management of CV risk factors during the wait-list period is clearly needed in these high-risk patients, and it is tempting to speculate that more aggressive cardioprotective measures may have decreased CV events. Similar to other studies in patients with chronic kidney disease (13), we found infrequent use of cardioprotective medications. Adoption of a predictable organ allocation strategy to facilitate a more detailed patient review in the months preceding transplantation and implementation of prophylactic measures that have been shown to decrease perioperative risk for nontransplant surgery may also be an effective strategy to decrease CV events in transplant candidates. Finally, a shift in clinical emphasis during the first posttransplantation year to include CV risk reduction in addition to monitoring allograft function and immunosuppression may be beneficial.
The initial cardiac investigation of patients in the low, intermediate, and high cardiac risk groups was not protocol driven; thus, conclusions regarding the overall value of cardiac investigation are not possible from this study. However, among patients who were activated to the waiting list and underwent initial noninvasive cardiac investigation, we found that the test outcome was not predictive of the time to CV event. It is important to note that the majority of abnormal noninvasive tests were MIBI. Our classification of abnormal echocardiograms (ejection fraction Ͻ40%) only considered systolic function and does not include an assessment of left ventricular hypertrophy or diastolic dysfunction, which also may be important considerations. These findings suggest that the timing of patient reevaluation in low-, intermediate-, and high-risk patients can be determined independent of the initial noninva- b Per 100 patient-years. c Among patients with normal tests before wait-listing, surveillance cardiac investigation is recommended annually in diabetic patients, biannually in patients with a history of IHD or PVD, and every 3 yr if patients are at low risk (i.e., no diabetes, IHD, or PVD). In patients with abnormal tests before wait-listing, surveillance cardiac investigation is recommended annually in those with no revascularization or PTCA and after 3 yr and then annually in those with successful CABG. sive cardiac test results and challenge recent recommendations for patient reevaluation that place a significant emphasis on the results of the initial cardiac investigations.
The optimum strategy for monitoring the cardiovascular fitness of wait-listed candidates is uncertain and has significant cost implications. Recent analyses of cardiac event rates after transplantation and the use of diagnostic tests among waitlisted Medicare patients revealed high perioperative event rates despite the frequent use of cardiac investigations during the wait-list period (2) . Currently, there are few data regarding the periodic rescreening of wait-list patients with noninvasive cardiac investigations. In one study of 193 patients with serum creatinine Ͼ2.5 mg/dl (only 10 dialysis patients were included), the cardiac event rate after normal dobutamine echocardiography increased from 8 to 16% between 24 and 40 mo after testing (14) .
Our practice of surveillance cardiac testing was based on clinical assessment of an individual patient's ongoing risk for cardiac disease and therefore differs from a protocol-driven approach that is based on waiting time alone. The low CV event rate among patients with fewer than the recommended number of surveillance investigations suggests that clinicians were able to assess risk correctly among wait-listed individuals and investigate those at highest risk more frequently. The possibility that more frequent investigation may have prevented CV in patients with fewer than the recommended number of investigations cannot be excluded from this observational study. Given the high cost of cardiac investigations and the uncertainty regarding the use of such investigations highlighted in our study, further studies to define the optimum use of surveillance cardiac investigations are warranted.
The unique demographic features of our patient population, the observational nature of our study, and our inability to define precisely the reasons underlying the clinical decisions made by the transplant physicians should be considered when interpreting the results of this study. Our initial risk stratification has not been validated. However, we believe that in the absence of a validated index to predict perioperative events in renal transplant candidates and with the limitations of the Framingham risk index (15) (e.g., limited relevance for predicting risk during surgery and in patients with established heart disease, underestimation of risk in transplant recipients [16] ), our risk stratification, which includes comorbid conditions (IHD and diabetes) that are predictive of posttransplantation ischemic events (17) (18) (19) (20) (21) , is justified. The possibility of an incidence prevalence bias is unlikely in our study because the same transplant physicians assessed our patients and there were no changes in the clinical approach to patient evaluation during the study period. In summary, our observations provide a detailed account of CV events among wait-listed patients and highlight several opportunities for both therapeutic intervention and possible cost and workload reduction. Our observations should provoke further prospective studies to define the optimum strategies for health maintenance in wait-listed individuals.
